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EXTENDED ABSTRACT !
In the last few years, YAP/TAZ emerged as powerful regulators of growth 
and tumor malignancy. YAP/TAZ are mainly regulated by two inputs: the Hippo 
pathway and biomechanical pathway. The latter involves structural and physical 
signals that cells receive from their being attached to the substrate and/or to other 
cells and that chance the tension and organization of the cytoskeleton and cell 
shape. In previous works from our laboratory, we indeed found that specific 
F-actin structures, such as bundled F-actin cables and stress fibers, are required to 
sustain YAP/TAZ activity. But the cascade intervening between F-actin and 
YAP/TAZ remains a mystery.  
In an independent research line, we also advanced on the biological effects of 
YAP/TAZ and found that overexpression of YAP in terminally differentiated cells, 
such as primary neurons, can trigger their dedifferentiation and acquisition of 
neural stem cells traits. YAP/TAZ can thus overcome the epigenetic barriers 
associated to terminal differentiation, but the underlying mechanisms are 
unknown. 
The work here described represents both an advancement and a merge of 
these two research lines. To start, we identified by Mass spectrometry (MS) YAP 
binding proteins whose interaction is regulated by F-actin. Next, we functionally 
validated the candidate regulators emerging from this proteomic approach by 
carrying out siRNA knockdown of the candidates and monitoring the 
consequences on YAP target gene expression by RT-PCR. Among these 
functionally validated YAP-binding proteins, our attention was captured by 
members of the SWI/SNF chromatin-remodeling complex, which includes 
important tumor suppressors. We confirmed the biochemical interaction between 
F-actin, SWI/SNF complexes and YAP by independent approaches, and found 
that YAP interacts with ARID1A. Interestingly, in the presence of F-actin, YAP 
fails to associate to SWI/SNF factors. At the biological level, we found that 
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ARID1A and BRM are key element of an epigenetic barrier that preserves the 
neuronal differentiated state.  
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ABSTRACT 
 
In the last few years, YAP/TAZ emerged as powerful regulators of growth 
and tumor malignancy. YAP/TAZ are regulated by two inputs: the Hippo pathway 
and biomechanical pathway. The latter involves structural and physical signals 
that cells receive from their being attached to the substrate and/or to other cells 
and that chance the tension and organization of the cytoskeleton and cell shape. In 
previous works from our laboratory, we indeed found that specific F-actin 
structures, such as bundled F-actin cables and stress fibers are required to sustain 
YAP/TAZ activity. But the cascade intervening between F-actin and YAP/TAZ 
remains a mystery. In an independent research line, we also advanced on the 
biological effects of YAP/TAZ and found that overexpression of YAP in 
terminally differentiated cells, such as primary neurons, can trigger their 
dedifferentiation and acquisition of stem cells traits. The work here described 
represents both an advancement and a merge of these two research lines. 
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SOMMARIO (Italiano) 
 
YAP e TAZ sono stati oggetto di grande attenzione alla luce del loro ruolo 
come regolatori della proliferazione cellulare. YAP e TAZ sono regolati 
principalmente da due tipi di segnali: la via di Hippo e la meccanotrasduzione. 
Quest'ultima comprende genericamente tutta una serie di segnali di contesto che 
fanno parte della fisicita' e struttura del microambiente, in primis l'attacco delle 
cellule alla matrice extracellulare ed altre cellule. Questi segnali, hanno la loro 
natura nelle forze fisiche che le cellule percepiscono e a cui rispondono grazie alla 
contrattilita' ed organizzazione tridimensionale del citoscheletro. L'equilibrio di 
queste forze genera la forma della cellula. In precedenti studi, il nostro gruppo ha 
chiarito come speciali strutture di F-actin siano importanti per l'attivita' o 
inibizione di YAP/TAZ da parte dell'ambiente. Ma i meccanismi della 
meccanotrasduzione restano enigmatici. In una linea di ricerca indipendente, 
abbiamo anche prodotto degli avanzamenti sul ruolo biologico di YAP/TAZ ed 
una scoperta particolarmente intrigante e' stata che esprimendo YAP (o TAZ) in 
cellule terminalmente differenziate quali i neuroni si osserva che questi 
dedifferenziano e diventano molto simili a normali cellule staminali neuronali 
(NSCs). Il lavoro qui descritto rappresenta sia un avanzamento in queste direzioni 
di ricerca che un loro inaspettato punto di contatto. 
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INTRODUCTION 
 
YAP/TAZ and the Hippo pathway 
YAP (Yes associated protein) and TAZ (transcriptional coactivator with 
PDZ-binding motif, also known as WWTR1) are transcriptional modulators that 
are fundamental to regulate tissue growth and organ size. YAP/TAZ 
transcriptional activities are regulated by several mechanisms. YAP/TAZ are 
classically considered to be regulated by the Hippo pathway (Zhao et al., 2011a). 
The core signaling pathway comprises a cascade of phosphorylations: the Sterile 
20-like kinases MST1 and MST2, activated by WW45 (also known as SAV1), in 
turns directly phosphorylate the large tumor suppressor homolog kinases 
LAST1/2. LAST1/2 then phosphorylate YAP/TAZ at multiple residues and 
inactivate them. Indeed, some of these LATS-phosphorylated residues (including 
YAP Ser127 and TAZ Ser89) have been found to promote 14-3-3 protein binding, 
as such preventing YAP/TAZ from translocation into the nucleus (Zhao et al., 
2011); others have been proved as critical for proteosomal recognition and 
degradation. Conversely, when the Hippo pathway is not active, 
unphosphorylated YAP/TAZ can bind to the transcription factors TEAD (TEA 
domain family member) in the nucleus and promote proliferation or stem cells 
self renewal (Ramos and Camargo, 2012; Zhang et al., 2009) (Figure 1A). 
However, in recent years, several variations on this basic signaling module have 
been reported, including LATS-independent phosphorylation of YAP/TAZ, 
MST-independent activation of LATS, phosphorylation-independent modalities of 
YAP/TAZ controls and others, such as the Wnt pathway (Azzolin et al., 2012; 
Shao et al., 2012), the TGF-beta pathway (Varelas et al., 2008) and the GPCR 
pathway (Yu et al., 2012).  
In previous work from our laboratory, we discovered a new mechanism of 
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YAP/TAZ regulation by extracellular matrix (ECM) and physical/mechanical 
inputs, operating through the F-actin cytoskeleton (Dupont et al., 2011). As such, 
the definition of YAP/TAZ as mediators of the Hippo pathway has been 
progressively changed to include clear non-hippo regulations and probably other 
pathways feeding on YAP/TAZ activity. 
YAP/TAZ and mechanical cues. 
One of the most fascinating aspects of YAP/TAZ biology is their regulation 
by structural elements that originate from the tissue. These can be summarized as: 
i) the cytoskeleton tension and cell-cell junctions that keep cells, tissues and 
organs in a certain shape; ii) adhesion of a cell to its surrounding extracellular 
matrix (ECM) (Halder et al., 2012). These structural elements can inform cells 
about the status of the tissue in which they are embedded, such as organ size and 
three-dimensional organization. When cells receive the information from these 
structural elements, cells regulate the activity of YAP/TAZ to promote 
proliferation or stem cell self renewal. These regulations offer the unprecedented 
opportunity to explore one of most mystery events in the biology, that is, wiring 
signal transduction and cell biology at the tissue level.  
YAP and TAZ are regulated by ECM stiffness, cytoskeletal tension and cell 
shape (Dupont et al., 2011; Wada et al., 2011). When cells are seeded on a stiff 
ECM, YAP/TAZ are nuclearly localized and transcriptionally active, whereas 
they are inhibited and relocalized in the cytoplasm when cells are seeded on a soft 
ECM (Dupont et al., 2011). Cell shape can be controlled by seeding cells on 
microprinted fibronectin “islands” of different sizes (Chen, 1997). In spread cells 
(cells growing at low density on plastic dishes, seeded on “big” fibronectin islands 
or stretched by mechanical force), YAP/TAZ are well active. But when cells grow 
as small, roundish, or unspread (seeded on small “islands”) units, YAP/TAZ are 
inactivated (Dupont et al., 2011; Wada et al., 2011; Aragona et al., 2013)(Figure 
1B). 
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Crucially, YAP/TAZ are the key mediators in the biological effects of ECM 
stiffness and cell shape. For example, when forced to remain small, endothelial 
cells die, while they proliferate when they are allowed to spread (Chen et al., 
1997). We can rewrite this behaviors by artificially change YAP/TAZ levels: if 
YAP/TAZ are artificially increased in small cells, cells start to proliferate; in 
contrast, attenuation of YAP/TAZ in spread cells causes them to die (Dupont et al., 
2011). Contact inhibition of growth of epithelial cells in high cell density is 
paralleled by YAP/TAZ inhibition. Although traditionally cell-cell contact 
inhibition is associated to the Hippo cascade, new evidence suggests that contact 
inhibition may also be considered as a consequence of the reduced cell shape, due 
to the confinement of cell-ECM adhesion area (reviewed in (Halder et al., 2012)).  
Interestingly, the regulation of YAP/TAZ by mechanical cues is different 
from their regulation by the Hippo pathway. Indeed, lowering mechanical cues 
leads to YAP/TAZ phosphorylation (degradation) and cytoplasmic relocalization 
in epithelial, mesenchymal post-EMT cells, as well as in cells expressing LATS 
insensitive YAP, or depleted of LATS (Dupont et al., 2011; Aragona et al., 2013). 
Mechanical cues and cell shape are associated to the regulation of the Rho family 
of small GTPase, of ROCK, MLCK and to corresponding changes in the tensile 
properties and dynamics of the actomyosin cytoskeleton (Mammoto and Ingber, 
2009; Parsons et al., 2010; Wozniak and Chen, 2009). In line with this notion, 
YAP/TAZ activities are dependent on this cytoskeletal pathway (Dupont et al., 
2011; Fernández et al., 2011; Sansores-Garcia et al., 2011; Wada et al., 2011; 
Zhao et al., 2012). Effective disruption of the F-actin cytoskeleton causes 
inactivation of YAP/TAZ in a way that is independent from LATS (Dupont et al., 
2011). Further more, if we deplete F-actin-capping/severing proteins Cofilin, 
CapZ, and Gelsolin in cells seeded in lower mechanical cues, YAP/TAZ activity 
is restored (Aragona et al., 2013). This indicates that cytoskeletal inputs are 
simply fundamental signals of YAP/TAZ activity, and that, probably, other 
regulations at the level of the Hippo cascade or other inputs may cooperate or 
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modify but not overrule the information of the mechanical context (Halder et al., 
2012).  
The biological functions of YAP/TAZ: growth, cell plasticity and endowing 
stemness properties  
YAP/TAZ are endowed with potent biological properties. YAP/TAZ are well 
known, at least in cell lines, to be able to overcome inhibition of cell proliferation 
caused by "contact inhibition"(Gumbiner and Kim, 2014). Mechanistically this is 
mediated by YAP/TAZ acting directly on enhancers of a host of target genes that 
control S-phase entry and mitosis (Zanconato et al., 2015). In addition, YAP/TAZ 
control genes involved in escaping apopotosis and promoting survival (Basu et al., 
2003; Huang et al., 2005).  
The classic and perhaps more visually revealing phenotype of YAP/TAZ is 
induction of organ overgrowth. Indeed, inactivation of Hippo pathway 
components causes organs to grow from fetal development to adulthood well 
beyond their normal size, generating hearts, livers and stomachs that are manyfold 
bigger than normal/wild-type organs(Piccolo et al., 2013; Zhao et al., 2011b). 
Intriguingly, this is reversible, as when YAP/TAZ return to normal levels, the big 
organ shrinks back to its correct size, losing the excess of cells by apoptosis. It 
thus appears that an organ can communicate to each of the cells that compile their 
information on what should be the organ's "correct" size and to proliferate or to 
stop proliferate depending on whether this inner benchmark is either yet to be 
reached or has been surpassed. The nature of this information is entirely 
mysterious, but it is unlikely to be provided by short-range chemical signals, such 
as diffusible growth factors; moreover diffusion of any chemical entity is unlikely 
to provide fine-grained spatial control over cell behavior, differentiation and death 
that instead occur during organ growth and remodeling. In contrast, mechanical 
signals can travel at great speed and distance due to the pre-stressed and 
essentially isometric tension of the extracellular matrix and cell cytoskeleton in 
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constant "tug of war" equilibrium between each other through focal adhesion and 
adhesive junction. Similar to vibrations of a guitar cord, changes in the cell's local 
mechanics can resonate through the tissue to be perceived by the whole organ and, 
viceversa, mechanical signals born at the tissue geometrical and architectural level 
can target each individual cell with nanometer accuracy, for example instructing 
the proliferation of a specific cell living in a specific mechanical niche (e.g. at a 
given location within a gland) but not its neighbor. This represents a speculative 
theory at the moment, but it is nevertheless intriguing that increasing tension in 
the cytoskeleton of mice lacking the actin severing proteins ADF and cofillin has 
been associated to dramatic tissue overgrowths (Kanellos et al., 2015). 
The role of YAP/TAZ in adult tissues has also started to be explored by 
using conditional knockouts. The general theme emerging is that, just like 
YAP/TAZ activation is instrumental for organ growth in embryos, they are 
dispensable for homeostasis of adult tissues. And, nevertheless, they remain 
essential for tumorigenesis initiated by loss of Hippo signaling (Cai et al., 2010; 
Lu et al., 2010), chemical carcinogenesis (Zanconato et al., 2015) and common 
oncogenic lesions (Da et al., 2009; Lau et al., 2014). On one hand, this specific 
requirement makes YAP/TAZ very appealing targets for therapeutic intervention. 
On the other, the relevance of YAP/TAZ is not an invention of cancer cells, but it 
rather represents the co-option of a physiological function, that is the role of 
YAP/TAZ for tissue repair. YAP/TAZ are indeed relevant for wound healing in 
all the tissues in which they have been knocked out: in the intestine, lack of 
YAP/TAZ causes very rapid cell death because of lack of repair of intestinal 
mucosa in models of colitis or irradiation (Gregorieff et al., 2015); in the liver, 
gain-YAP/TAZ triggers repair after chemical injury (Nejak-Bowen et al., 2015) 
and in the heart, reactivation of YAP/TAZ can regenerate the myocardium after 
infarction (Lin and Pu, 2014; Xin et al., 2011). The dual requirement of 
YAP/TAZ in cancer and regeneration is in line with the notion that cancer does 
not necessarily divert normal stem cell programs, as it is often discussed; rather, it 
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recapitulates aspect of embryonic or of adult tissues under special conditions, 
such as stressed, damaged, inflamed tissues that are in fact conditions requiring 
growth and de novo regrowth, tissue remodeling and cell plasticity. Importantly, 
evidence exists that "professional" somatic stem cells may not be only or even the 
leading actors of wound repair (Carlén et al., 2009; Ito et al., 2005); by lineage 
tracing, it has been demonstrated that the healing microenviroment can actually 
trigger de-differentiation of committed progenitors, if not fully differentiated cells, 
back to a stem cell status (Yimlamai et al., 2014a; Zhao et al., 2014). In other 
words, in order to match its needs, the tissue "calls on stem cell duty" cells that 
would normally only leave the stem cell niche to differentiate and die, reverting 
the differentiation process. The mechanisms of this de-differentiation are 
unknown but certainly entail a combination of chemical (ie. Interleukins, TGFb 
and other cytokines of the wound healing microenvironment)(Coussens and Werb, 
2002; Mast and Schultz, 1996) and physical cues (cell spreading over the exposed 
ECM, loss of contact inhibition, stiff/activated fibroblasts, de novo deposition of 
specific matrix protein - such as laminin 11 - all in turn feedbacking on cell 
contractility and viceversa)(Hashimoto et al., 2004; Tsuruta et al., 2011). The 
involvement of YAP/TAZ in these events is well-established and may explain 
why YAP/TAZ are so crucial for repair and cancer: not only they are inhibited by 
and relevant for contact inhibition and cell mechanical cues, but they may be also 
fundamental for dedifferentiation and de-novo generation of somatic stem cells 
from more differentiated cells. The latter is one of the themes of this thesis, for 
which I collaborated with and build on the work of my colleagues Tito Panciera, 
Luca Azzolin, Atsushi Fujimura and others, who found that inducing YAP/TAZ 
expression in differentiated cells of various histotypes induces them to regress to 
the corresponding lineage-specific somatic stem cell status. YAP/TAZ expression, 
as shown here, can turn neurons (or astrocytes) into neural stem cells; or turn 
luminal differentiated cells of the mammary gland into Mammary stem cells, and 
pancreatic exocrine cells into pancreatic progenitors (Figure 1C). 
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The ability of YAP/TAZ to overcome the barriers of differentiation may 
occur in vivo, as in livers of transgenic mice the overexpression of YAP 
transdifferentiated hepatocytes in bile-duct-like cells (Fitamant et al., 2015; 
Yimlamai et al., 2014b). The role of YAP/TAZ in dedifferentiation also resonates 
with an even earlier requirement of TAZ in breast cancer. Michelangelo 
Cordenonsi and colleagues had shown that TAZ expression correlated to cancer 
stemness genetic signatures; YAP/TAZ are not ubiquitously expressed in tumor 
cells but are specifically enriched in cancer initiating stem cells (Cordenonsi et al., 
2011). Strikingly, expression of TAZ does not simply expand the cancer stem cell 
populations; rather it converted non-stem tumor cells into cancer stem cells 
(Cordenonsi et al., 2011). This concept may be actually rephrased in a slightly 
different way: TAZ expression cause dedifferentiation of more differentiated and 
more benign tumor cells into their more aggressive and plastic mother cells, 
expanding their number not (just) by promoting their proliferation but by 
enlarging their number by cooptation of other cells into a more progenitor-like 
cellular state. Obviously, these events do not occur randomly or interest all cells, 
neither in wound healing nor in cancer tissues. YAP/TAZ activity need to be 
spatially controlled and even in the most aggressive tumors, YAP/TAZ remains 
dependent on "ground control", that is to the structural features of the specific 
environment to which they are attached (Zanconato and Piccolo, 2015). In other 
words, mechanical signals are also important to instruct which cells express 
sufficient YAP/TAZ to induce them to be stem cells. 
These perspectives brings back the focus to what are the signals that are 
relevant for YAP/TAZ mechanotransduction. And this is the starting point of this 
thesis. By Mass Spectrometry, we identified SWI/SNF as regulators of YAP/TAZ 
activity during differentiation and as candidate sensors of mechanotransduction. 
SWI/SNF as epigenetic regulators of chromatin structure 
There are two classes of complexes regulating chromatin structure: i) 
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complexes that covalently modify histone tails; and ii) ATP-dependent complexes 
that remodel nucleosomes. These two classes cooperate to regulate the structure of 
chromatin dynamically, and thus control gene expression. On the basis of subunit 
composition and biochemical activity, the ATP-dependent chromatin remodellers 
can be further divided into families, including SWI/SNF, ISWI, INO80, SWR1 
and NURD/Mi2/CHD complexes. Among these, SWI/SNF complexes are 
emerging as bona fide tumor suppressors, as they have been found to be 
specifically inactivated by mutations in several human cancers (Wilson and 
Roberts, 2011). 
SWI/SNF chromatin remodeling complexes constitute a highly related 
family of evolutionarily conserved multisubunit complexes (Figure 1D). 
SWI/SNF complexes have several functions. They modulate gene expression by 
interacting with transcription factors, coactivators, and corepressors, and they 
mobilize nucleosomes at target promoters and enhancers (Hu et al., 2011; 
Tolstorukov et al., 2013; Yu et al., 2013). They also have been implicated in 
various types of DNA repair (Dykhuizen et al., 2013; Gong et al., 2006; Hara and 
Sancar, 2002; Park et al., 2006; Watanabe et al., 2014). 
SWI/SNF in Cancer 
In the late 1990s, the first clue linking SWI/SNF complexes to cancer was 
the discovery of mutations of SNF5 in rhabdoid tumors (RTs), a rare but highly 
aggressive type of cancer (Biegel et al., 1999; Versteege et al., 1998). In 
genetically engineered mouse models, Snf5 was subsequently validated as potent 
and bona fide tumor suppressor (Guidi et al., 2001a; Roberts et al., 2002) 
Although this observation has been first noted over a decade ago, only more 
recently it has been discovered that many types of cancer have SWI/SNF subunit 
mutations thanks to cancer genome sequencing studies. At least nine genes 
enconding for subunits of SWI/SNF complexes have been identified as 
recurrently mutated in cancers derived from nearly every tissue in the body, and 
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collectively occurring in 20% of all human cancers (Helming et al., 2014; Wilson 
and Roberts, 2011). The function of mutated SWI/SNF complexes in cancer and 
the mechanisms!by!which!mutations in individual subunits promote oncogenesis 
are now active areas of research. 
The role of SWI/SNF in lineage specification.  
In the lineage-specific differentiation, SWI/SNF complexes play important 
roles. Essential roles of the SWI/SNF complexes have been identified during 
neurogenesis, adipogenesis, myogenesis, osteogenesis and haematopoiesis, and 
the complexes are involved in the differentiation of many other lineages (de la 
Serna et al., 2006; Flowers et al., 2009; Young et al., 2005). During differentiation, 
tissue-specific transcription factors cooperate with SWI/SNF complexes to 
coordinately balance the suppression of proliferation programs and the activation 
of lineage-specific genes. Despite these roles, how the complexes achieve specific 
regulation of gene expression remains misty. 
It seems that mammalian SWI/SNF complexes are highly heterogeneous, 
from the point of view of both composition and differential presence in different 
tissues. In addition to core subunits, which are expressed in all lineages, the 
SWI/SNF complexes contain variant subunits that is restricted in specific lineages 
or tissues. For example, it has been discovered that several neural-specific 
subunits can distinguish post-mitotic mature neurons from neural progenitors. 
These variant complexes could control gene expression programs, which are 
required for the neuron terminal differentiation (Lessard et al., 2007; Wu et al., 
2007). Based on the large number of subunits, and the tissue-specific composition 
of the complexes, it has been estimated that hundreds variants of SWI/SNF 
complexes might exist (Wu et al., 2009), which bind lineage-specific transcription 
factors and modulate specific loci. Thus, during the control of these 
developmental programs, specificity of SWI/SNF complexes is achieved in part 
through restricted expression and in part through combinatorial assembly of 
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variant SWI/SNF subunits. The BAF60C (SMARCD3) subunit is specifically 
expressed in the embryonic heart, where it is essential for the cardiac development 
(Lickert et al., 2004). Similarly, it has been reported that a switch from the 
BAF45A (PHF10) and BAF53A (ACTL6A) subunits, that are specific expressed 
in neural progenitors, to BAF45B (DPF1), BAF45C (DPF3), and ACTL6B 
(BAF53B) subunits is essential during the transition of neural stem cells into 
post-mitotic neurons (Lessard et al., 2007; Wu et al., 2007). Such switching can 
facilitates differential activation of transcriptional pathways by modulating its 
interaction with specific transcription factors (Kadam, 2000).  
Analogously, in ES cells there is a unique combination of core SWI/SNF 
components and associated factors. Through regulating pluripotency and 
self-renewal, the SWI/SNF complex contribute to the maintenance of this lineage 
(Gao et al., 2008; Ho et al., 2009; Kidder et al., 2009; Yan et al., 2008). Mouse 
embryos lacking the SWI/SNF subunits ARID1A, BRG1, SNF5 or BAF155 die 
near the peri-implantation stage of development, shortly after ES cells are formed 
(Guidi et al., 2001b; Klochendler-Yeivin et al., 2000; Roberts et al., 2000). In 
cultured ES cells, inactivation of BRG1 or ARID1A leads to defects in 
self-renewal and promotes differentiation (Bultman et al., 2000; Ho et al., 2009). 
As ES cells are the only known cell type in which BAF155 can replace BAF170, 
a unique subunit composition may contribute to these roles (Ho et al., 2009). This 
variant complex together with key pluripotency transcription factors, such as 
OCT4, NANOG and SOX2, co-localize at target gene promoters to facilitate ES 
cell-specific stem cell gene expression programs (Ho et al., 2009). Moreover, 
forced overexpression of the core SWI/SNF subunits BAF155 and/or BRG1 
enhances the reprogramming of fibroblasts into induced pluripotent stem (iPS) 
cells (Singhal et al., 2010), where they have been proposed to facilitate the 
binding of OCT4 to target genes. In primary embryonic fibroblasts, inactivation of 
Snf5 also leads to the upregulation of stem cell-associated signatures (Wilson et 
al., 2010). In Drosophila neuroblasts, ARID1a (or BRM) induces a transcriptional 
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program that initiates temporal patterning, limits self-renewal, and prevents 
dedifferentiation (Eroglu et al., 2014; Koe et al., 2014). Collectively, these studies 
establish that the SWI/SNF complex work as an important regulator in stem cell 
self-renewal and pluripotency, and raise the possibility that the oncogenic 
stimulus due the SWI/SNF mutations may be partly derived from SWI/SNF 
involvement in regulating the balance between self-renewal and differentiation.  
In primary embryonic fibroblasts, inactivation of SNF5 also leads to the 
upregulation of stem cell-associated signatures (Wilson et al., 2010). In 
Drosophila neuroblasts, ARID1a (or BRM) induces a transcriptional program that 
initiates temporal patterning, limits self-renewal, and prevents dedifferentiation 
(Eroglu et al., 2014; Koe et al., 2014). Collectively, these studies establish that the 
SWI/SNF complex work as an important regulator in stem cell self-renewal and 
pluripotency, and raise the possibility that the oncogenic stimulus due the 
SWI/SNF mutations may be partly derived from SWI/SNF involvement in 
regulating the balance between self-renewal and differentiation.  
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RESULTS 
 
YAP/TAZ are classically considered to be under the regulation of the Hippo 
signaling pathway, which culminates in YAP/TAZ phosphorylation by LATS1/2: 
this event prevents YAP/TAZ translocation into the nucleus (Zhao et al., 2011). 
Indeed, LATS-phosphorylated YAP/TAZ are cytoplasmic and inactive, whereas 
unphosphorylated YAP/TAZ escape their cytoplasmic anchors and enters in the 
nucleus where they can activate target gene expression. However, in previous 
work from our laboratory, we have established YAP/TAZ as sensors and 
mediators of mechanotransduction (Aragona et al., 2013; Dupont et al., 2011) in a 
Hippo-independent manner. We demonstrated that F-actin is the key unit in this 
pathway, and we identified the F-actin-capping/severing proteins Cofilin, CapZ, 
and Gelsolin as essential gatekeepers of F-actin-mediated YAP/TAZ regulation 
(Aragona et al., 2013). Cofilin, CapZ, and Gelsolin inhibit polymerization of 
F-actin and as such are upstream regulators of F-actin. Thus, the linkage between 
F-actin and YAP/TAZ still remains unknown. We initiated this study with the aim 
of identifying the missing linker in the F-actin-regulated YAP/TAZ activity. 
YAP/TAZ location does not always mean YAP/TAZ transcription activity 
In sparse culture conditions, YAP/TAZ are usually nuclearly localized and 
active (Dupont et al., 2011). We started our studies by noticing that sparse 
MCF10A mammary epithelial cells treated with Latrunculin A (0.5 µM, Lat.A), a 
drug that prevents F-actin assembly, however tend to relocalize YAP/TAZ out of 
the nucleus. Strickingly, this was dependent on the nuclear export machinery of 
YAP/TAZ, as concomitant treatment with Leptomycin B (15 ng/mL LMB, an 
inhibitor of chromosomal region maintenance/exportin1) rescued YAP/TAZ back 
to the nucleus (Figure 2A-C). As the nuclear localization of YAP/TAZ directly 
reflects their transcriptional activity, we next monitored their capacity to activate 
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target gene expression by measuring the mRNA level of the established 
YAP/TAZ targets CYR61 and ANKRD1(Zanconato et al., 2015). As expected, 
the expression of these genes is high in sparse cells and inhibited with Lat.A, in 
line with YAP/TAZ localization. However, in Lat.A-treated cells, LMB could not 
rescue CYR61 and ANKRD1 levels back to control levels, even though 
YAP/TAZ are nuclear in these conditions (Figure 2D and 2E). In conclusion, we 
found that, in the absence of intact F-actin, even if we artificially rescued 
YAP/TAZ nuclear localization, YAP/TAZ are still not transcriptionally active.      
Nuclear re-localized YAP/TAZ could not rescue mechanical-mediated loss of 
YAP/TAZ activity 
According to our previous work, YAP/TAZ are localized in the cytoplasm 
and, as such, transcriptionally inactive (Aragona et al., 2013; Dupont et al., 2011) 
in cells plated on a soft ECM or at high density, two conditions that are highly 
reminiscent of Lat.A treatment (see Figure. 2). Therefore, we wanted to check the 
effect of LMB on YAP/TAZ localization and activity in cells cultured at high 
confluence or on soft substrates (Figure 3A and 4A). We confirmed that 
MCF10A cells plated at high confluence or on a soft substrate (hydrogels of 0.7 
KPa, kindly prepared by Stefano Giulitti, in the laboratory of prof. Nicola 
Elvassore, Department of Industrial Engineering, University of Padova) displayed 
a cytoplasmic immuno-staining of YAP/TAZ and a low expression of their target 
genes compared to sparse cells or the same cells plated on stiff substrate, 
respectively (Figure 3B and 4B). As for Lat.A, also in these two set-ups, 
concomitant treatment with LMB could cause YAP/TAZ nuclear accumulation 
but could not rescue CYR61 and PTX3 expression back to control levels (Figure 
3D-E and Figure 4D-E). These data clearly demonstrate that in cells plated at 
high confluence or on soft substrates, as well as upon Lat.A treatment, YAP/TAZ 
transcriptional activity are inhibited even when YAP/TAZ are inside the nucleus. 
This suggests the existence of YAP/TAZ nuclear regulators that are under the 
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mechanical control.  
Biochemical screening for YAP/TAZ interactors 
Next we sought to identify nuclear regulator(s) of YAP/TAZ that are 
controlled by mechanical stimuli. Two hypotheses may explain the regulation of 
YAP/TAZ described in the previous paragraphs by mechanical cues: i) the 
existence of a protein “X” activated by intact F-actin and required to sustain 
YAP/TAZ function; the interaction between YAP and protein X is expected to 
decrease upon F-actin disassembly (i.e. Lat.A treatment); or ii) the existence of a 
protein “Y” inhibited by F-actin and usually functioning as a natural inhibitor of 
YAP/TAZ; the interaction between YAP and protein Y therefore is expected to be 
stabilized by disruption of the F-actin cytoskeleton (Figure 5A).  
In order to find out this(these) regulatory(ies) factor(s), we sought to identify 
the YAP/TAZ nuclear binding proteins that are modulated by cytoskeletal 
properties with a pull-down assay followed by mass spectroscopy. To do it in an 
unbiased way, we decided to compare the interactors of YAP in cells plated at low 
confluence with unrestrained adhesive area to those in cells treated with Lat.A, an 
inhibitor of F-actin formation that is functionally equivalent to mechanical 
conditions such as a soft ECM or a small ECM island (dense). First, we optimized 
a pull-down assay to isolate YAP/TAZ together with their interactors in MCF10A 
cells, as this cell line displays a strong YAP/TAZ regulation by mechanical cues 
and, in particular, by F-actin cytoskeleton. We used MCF10A cells 
stably-expressing Flag-tagged YAP 5SA and, as a (negative) control, MCF10A 
cells transduced with the corresponding empty vector. Both cell lines were left 
untreated or treated with Lat.A for 4 hours and then harvested (4 samples in total). 
Extracts were then subjected to anti-Flag IP and Western blot analysis for known 
interactors of YAP in order to validate our experimental set-up. Indeed, known 
YAP interacting proteins, such as TEAD1, AMOTL2 and LATS, were readily 
recovered from the eluate after Flag-YAP immunoprecipitation. To identify all 
! 24!
YAP interactors and especially those whose binding with YAP is sensitive to 
Lat.A, after immunoprecipitations the eluates were run in a 4-12% gradient 
SDS-PAGE and the gel was sent to the EMBL core proteomic facility for MS 
analysis (Figure 5B). The details of the preparation of the samples for the 
mass-spectrometric analysis will not be discussed here. Briefly, each sample lane 
was cut into five pieces according to molecular weight, and all the proteins 
contained in each piece subjected to in-gel tryptic digestion. The resulting 
peptides were purified and subjected to identification based on their mass 
according to EMBL parameters. We therefore obtained a list of proteins for each 
sample. From this list, we excluded the proteins aspecifically interacting with the 
anti-Flag beads used for the immunoprecipitation, that are: i) proteins that were 
equally represented in the immunoprecipitation from untreated control MCF10A 
cells and untreated Flag-YAP 5SA-expressing MCF10A cells; ii) proteins that 
were equally represented in the immunoprecipitation from Lat.A-treated control 
MCF10A cells and Lat.A-treated Flag-YAP 5SA-expressing MCF10A cells. 
As shown in Table 3, we could isolate some YAP-interacting proteins so far 
identified by similar approaches in the literature, like LATS, AMOTL2 and 
TEAD, that can be considered as positive controls/quality checks of our 
experiment (Figure 5C). Interestingly, we could also detect an interaction 
between YAP and Merlin/NF2 in extracts from MCF10A cells, likely representing 
an indirect interaction probably mediated by the LATS kinases (Yin et al., 2013a). 
Surprisingly, however, we failed to identify in our experiments interaction with 
MST kinases and Salvador, despite the presence of proteins that have been 
proposed to act more upstream than MST in the Hippo cascade, such as NF2 
which is in line with the discovery with Yin et al. (Yin et al., 2013b). As recently 
found in Couzens et al., 2013, we also found AMOTL1 and AMOTL2 in our MS 
approach. 
In order to be specific for the interaction, moreover, we set a cut-off to 
discriminate if a protein can be considered a real interactor of YAP: to do that, we 
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noticed that known interactors of YAP, such as the TEAD factors, display 4 or 
more specific peptides in the MS output. We therefore applied this criterion to all 
the MS results and found some other candidates for YAP interaction, as shown in 
Table 4. Among all, we looked at the candidates which are more likely sensitive 
to a regulation by mechanical cues, that are the candidates that display a number 
of detectable peptides changing between with and without Lat.A. Among these 
candidates the proteins of the SWI/SNF complex showed good value as YAP 
regulators. This is because: i) there are several proteins of SWI/SNF complex 
repeatedly represented in the candidate list (Table 4); ii) the ratio of detectable 
peptides between Flag-YAP-5SA pull down in Lat.A-treated vs Lat.A-untreated 
cells is high for each individual protein of the SWI/SNF complex; iii) nearly for 
all the detectable SWI/SNF complex components the binding to YAP in the Lat.A 
treated samples increases with compared to the untreated sample, suggesting that 
SWI/SNF might work as an inhibitor; iv) it has been reported that SWI/SNF 
complex can bind Actin-like proteins (Nishimoto et al., 2012; Rando et al., 2002; 
Szerlong et al., 2008; Zhao et al., 1998), which suggests its potential in 
responding to mechanical cues; v) the SWI/SNF complex usually works as 
regulator in nucleus (Kadoch and Crabtree, 2015; Wilson and Roberts, 2011; 
Zraly et al., 2006). 
Screening of MS results 
Next, we decided to validate the results from MS on the SWI/SNF 
interaction with YAP by loss of function assays. As this is a protein complex, we 
focused on the core component identified by MS. For this, we used independent 
siRNAs to treat MCF10A cells in order to knockdown ARID1A, SNF5, BRG1 
and BRM endogenous proteins, and to check by qRT-PCR how these 
knock-downs affect direct YAP/TAZ-regulated genes. As shown in the Figure 
6A-C, siRNAs against ARID1A and SNF5 efficiently knock-down ARID1A and 
SNF5 expression and the expression of CTGF in ARID1a- or SNF5-depleted cells 
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was greatly increased compared to siRNA control-treated cells. As positive 
control, siRNA against LATS induced CTGF expression 4 times more than 
siRNA control. The same results were also obtained by depletion of the catalytic 
ATPase subunits of SWI/SNF complex, BRG1 and BRM (Figure 6D-F). The 
results above suggest that SWI/SNF complex might work as YAP/TAZ inhibitors 
inside the nucleus. We confirmed the previous observations also by using the 
synthetic TEAD-dependent luciferase reporter (8xGTIIC-Lux) in HEK293 cells. 
HEK293 cells were plated in sparse conditions, transfected with siRNAs and 24h 
later with 8xGTIIC-Lux and CMV-LacZ (to normalize for transfection efficiency). 
Cells were then harvested 48 hours after DNA transfection. Indeed, we found that 
depletion of ARID1a or BRM dramatically increased the expression of the 
reporter compared to siRNA control-treated cells. Moreover, in both conditions, 
this was YAP/TAZ dependent, as depletion of YAP/TAZ in ARID1A-depleted 
and BRM-depleted cells abolished the above described induction (Figure 7).    
YAP interacts with SWI/SNF complex  
We wanted to repeat and validate the YAP-SWI/SNF protein-protein 
interactions previously detected by MS. To do so, we carried out 
co-immunoprecipitations of overexpressed YAP and individual SWI/SNF 
components upon co-transfection in HEK293T cells. For these assays, we decided 
to use HA-YAP 5SA, a YAP mutant for the LATS phosphorylation sites that 
favors YAP nuclear localization and that was originally used in the MS 
experiment. As shown in Figure 8A and 8B, we coprecipitated HA-YAP 5SA by 
pulling down Flag-tagged BRM or BRG1. As a control, transfected BRM or 
BRG1 retain their capacity to bind endogenous BAF53a, ruling out the possibility 
of artifacts due to these overexpression experiments. 
 BRG1 and BRM have been previously shown to bind nuclear actin-like 
molecules also known as BAF53a through a specific domain, called HSA domain. 
To test the involvement of this domain in the YAP/SWI-SNF interaction we 
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prepared a Flag-tagged HSA-deletion construct of BRG1 and repeated the 
coimmunoprecipitation experiments with YAP. As shown in Figure 8B lanes 5 
and 6, HA-YAP-5SA retained the ability to bind Flag-BRG1-ΔHSA indicating 
that this domain is dispensable for YAP/BRG recognition. As control of this 
deletion construct, only wild-type BRG1, but not HSA-deleted BRG1, interacted 
with BAF53a.   
Then, in order to exclude that the YAP/BRG1 interaction was specific of our 
experimental set up, we repeated the YAP-SWI/SNF interaction by using a 
distinct IP set up and different cellular context. For this, we employed the 
mammary immortalized cell line MCF10A stably transduced with Flag-YAP-5SA. 
Cell lysates from these cultures were used to first precipitate YAP (by using 
anti-Flag pull down) and then the presence of coprecipitating endogenous 
SWI/SNF proteins were monitored by western blotting. Indeed, Flag-YAP-5SA 
coprecipitated endogenous SWI/SNF proteins, including BRG1, BRM ARID1a 
and SNF5 (Figure 8C).  
Finally we sought to verify if these associations could occur in a completely 
endogenous set-up. SWI/SNF is a large protein complex made of several core 
subunits (BRG1, BRM and ARID1a) and some facultative components 
(SMARCC1, BAF53a and SNF5). We sought to identify which of these SWI/SNF 
component(s) is directly binding to YAP. For this, we purchased commercial 
antibodies against: ARID1a, BRG1, BRM, SMARCC1, BAF53a and SNF5. We 
found that purification of BRG1 or SMARCC1 triggers co-precipitation of all the 
other SWI/SNF subunits (For BRG1 pull-down we could identify SMARCC1, 
BAF53a and SNF5; For SMARCC1 pull-down we could identify BRG1, BAF53a 
and SNF5) with the exception of ARID1a and YAP. By using SNF5 antibodies, 
we could co-precititate SMARCC1 but none of the other components. This 
suggests that SWI/SNF may be heterogeneous in their molecular composition or 
that antibodies used to precipitate the complex may actually interfere with 
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complex assembly. Most importantly, when we precipitated the SWI/SNF 
complex with ARID1a we were able to detect coprecipitation of all the other 
endogenous components (including BRG1, SMARCC1, BAF53a and SNF5) and 
also coprecipitation of YAP. These results suggest that YAP association to 
SWI/SNF occurs only in ARID1a-containing SWI/SNF complexes (Figure 8D). 
Taken together, the data support the notion that YAP interacts with SWI/SNF 
complex.  
YAP directly binds to ARID1a. 
The above results raised the possibility that ARID1a may be proximal or directly 
mediate YAP association to SWI/SNF protein complex. If so, then, depleting cells 
of the other SWI/SNF subunits should not affect the ARID1a/YAP association. 
To test this hypothesis, MCF10A cells were transfected with independent siRNAs 
against BRG1 and BRM. By using these BRG1 and BRM-depleted lysates, we 
found that endogenous YAP/ARID1a interaction remained well-detectable 
(Figure 9A, lanes 5 and 6) in a way that is comparable to co-IPs from lysates of 
siRNA-control transfected cells (Figure 9A, lanes 3 and 4). As control, 
knockdown of BRG1/BRM disabled the ability of ARID1a to complex with 
BAF53a, a finding in line with the published literature that BAF53a directly binds 
BRG1/BRM, and only indirectly to ARID1a (Szerlong et al., 2008). In other 
words, our findings suggest that YAP is more likely to directly bind ARID1a, and 
that ARID1a serves as a link between YAP and the rest of the SWI/SNF complex. 
To further prove this hypothesis, we knocked down ARID1a and test the effects 
of this depletion on a BRG1-YAP co-IP. As shown in Figure 9B, loss of ARID1a 
impairs BRG1-YAP interaction (lanes 5 and 6). In contrast knockdown of other 
SWI/SNF subunits, such as BAF53a and SNF5, had no effect on BRG1-YAP 
interaction. The data described above indicate that ARID1a is a bridge for the 
association between YAP and SWI/SNF complex. 
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YAP binds to ARID1a through its WW domain. 
The data presented so far indicates that YAP binds to SWI/SNF likely 
through ARID1a. With this background in mind, we decided to investigate which 
domain of YAP is directly involved in ARID1a binding. YAP display different 
domains, including PDZ Binding motif, TAD (Transcription Activation Domain), 
Coiled-Coil Domain, WW domain, TEAD Interacting Domain, and a number of 
YAP interactors have been demonstrated to bind YAP in different domains 
(Figure 10A) (Oren, 2013)(Piccolo et al., 2014). In order to find the exact domain 
of YAP involved in YAP binding to SWI/SNF protein complex, we carried out 
structure-function studies in HEK293T cells between overexpressed YAP and 
endogenous proteins. For this, we prepared C-terminus deletion constructs of 
Flag-YAP that progressively eliminate from YAP protein sequence three of its 
domains, that are the PDZ, the TAD and the WW domains (Figure 10B). 
HEK293T cells were then transfected with the indicated YAP deletion constructs 
and protein extracts were subjected to anti-Flag IP and analyzed for 
coprecipitating endogenous ARID1a, BRG1 and SNF5. As shown in Figure 10C, 
these SWI/SNF proteins strongly associated to Flag-YAP-ΔPDZ+ΔTAD but not 
Flag-YAP-ΔPDZ+ΔTAD+ΔWW. This implies that SWI/SNF complex might 
bind to YAP WW domain. As controls of the previuos IP experiments, 
YAP/AMOT and YAP/PTPN14 associations were lost after deletion of the YAP 
WW domain, whereas YAP interaction with TEAD4, reported to happen through 
the N-terminus part of YAP and independently of the WW domain, was present in 
all the deletion constructs of YAP here analyzed. 
To strengthen these data, we obtained another YAP construct that is mutated only 
in the WW domain (Tryptophan 258 to Alanine; Proline 261 to Alanine) and 
found that, compared to wt, YAP WW mut interaction with ARID1a and SNF5 
(as well as with AMOT and PTPN14) were completely lost. In contrast, YAP 
WW mut could still precipitate TEAD4, ruling out the possibility that WW 
mutation could compromise YAP structure and the general possibility of YAP to 
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interact with other proteins (Figure 10D). Of note, YAP/TEAD interaction is 
impaired only if the Serine 94 of YAP, specific for TEAD binding (Zhao et al., 
2008), is mutated to Alanine. 
In conclusion, we have demonstrated that YAP binds to SWI/SNF protein 
complex, more likely through interaction with ARID1a, and that YAP WW 
domain is required for this interaction.  
 
F-actin binds to SWI/SNF complex  
We next decided to evaluate the interaction between Actin and the SWI/SNF 
complex in our cellular models. This interaction has been previously documented 
for BRG1 and in particular the HSA domain of BRG1 was found to be important. 
(Zhao et al., 1998, Rando et al., 2002 and Szerlong et al., 2008). As Actin is 
present in the cell mainly as G- (monomeric) or F-(polymerized) actin, we 
decided to analyze these two pools and their interaction capacity with SWI/SNF 
complex. In the usual conditions for immunoprecipitation (high detergents in the 
buffer, high salt concentration, without ATP providing energy, low temperature), 
formation of G-actin is favored and BRG1 failed to interact with actin. We also 
optimize the experimental conditions that favor F-actin stabilization and analysis 
from cell lysates. For this, we used biotinilated-phalloidin (Bio-Phall), a reagent 
that can stabilize F-actin and that enables us to selectively precipitate F-actin and 
F-actin-interacting proteins with a streptavidin resin (Figure 11A). In the F-actin 
pull-down assay with Bio-Phall, we could precipitate the SWI/SNF protein 
complex components ARID1a, BRG1, SMARCC1, SNF5, BAF53a and gelsolin, 
a known F-actin-interacting protein (positive control) (Szerlong et al., 2008). 
Lysates from LatA-treated cells were used as negative control. Indeed, by 
inducing F-actin disassembly, LatA impedes Bio-Phall integration in F-actin 
fibers, and, as such any pull-down (Figure 11B). These results demonstrate that 
SWI/SNF protein complex can associate with F-actin. 
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F-actin binding to SWI/SNF cause YAP to dissociate from SWI/SNF 
Our findings present the evidence that YAP directly binds to SWI/SNF 
complexes and F-actin is associated to SWI/SNF complexes. Then, we decided to 
investigate the relationship between SWI/SNF, F-actin and YAP. To address this 
point, we employed co-immunoprecipitation assays to pull down endogenous 
YAP in MII cells treated with either Lat.A (i.e. NO F-actin) or phalloidin (i.e., 
PLUS F-actin), and we then checked by western bolt the coprecipition of 
SWI/SNF protein complex components. As shown in the Figure 11C, in the 
presence of intact F-actin (with Phalloidin), the endogenous YAP-SWI/SNF 
association was absent (lane 4): however, upon disruption of F-actin cytoskeleton 
(with Latrunculin A), YAP-SWI/SNF association became evident (lane 3). The 
result above suggests a model for the regulation of the nuclear activity of YAP by 
F-actin: when cells are highly packed or plated on a soft ECM, the F-actin 
cytoskeleton is disrupted and YAP is inhibited by SWI/SNF complex; when cells 
are cultured at low confluence or on a stiff ECM, F-actin is activated and YAP is 
released from SWI/SNF complex. We found before that ARID1a was the bridge 
between YAP and SWI/SNF complex. Therefore, we want to further test if 
ARID1a was still important in mechanical regulated YAP-SWI/SNF association. 
To do so, we repeated the endogenous YAP immunoprecipition in extracts from 
LatA-treated cells in the presence or absence of ARID1A to check how these 
conditions affect YAP interactors. Upon ARID1a depletion, the interaction 
between YAP and the SWI/SNF protein components BRG1, SMARCC1, and 
SNF5 was abolished in Lat.A-treated cells (Figure 11D, lane 5 and 6). 
The data presented so far provide strong biochemical evidence that YAP 
could interact with SWI/SNF only when F-actin is not associated to the SWI/SNF 
complex. 
 
Knockdown of ARID1a rescue YAP activity from mechanical regulation 
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We have demonstrated that YAP directly binds to SWI/SNF protein complex, 
and we hypothesized that this represented an inhibitor regulation of YAP (Figure 
8-11). According to this model, if we induce the depletion of the SWI/SNF 
complex, we should restore YAP/TAZ activity in mechanically-inhibited cells 
(cells plated at high density or on soft ECM). Since knockdown of ARID1a could 
not affect YAP/TAZ localization in high confluent cells (data not shown), we 
decided to use LMB to relocate YAP/TAZ into nucleus. We previously showed 
that even if YAP/TAZ were nuclear because of LMB treatment, YAP/TAZ were 
inactive in densely packed cells (Figure 3). As we found that ARID1A is a 
mechano-sensitive nuclear inhibitor of YAP/TAZ, we indeed argued that 
depletion of ARID1A could rescue the previous transcriptional inhibition of YAP. 
To test this hypothesis MCF10A cells were first transfected with two independent 
siRNAs against ARID1A; next cells were replated at high density in the presence 
or absence of LMB; then cells were harvested for qPCR analysis (Figure 12A). 
Indeed, upon ARID1A depletion, highly-confluent MCF10A cells treated with 
LMB rescued CTGF and CYR61 expression (Figure 12B and 12C). 
 Next, we repeated the experiment in soft ECM. MCF10A cells were 
transfected with two independent siRNAs against ARID1a. The day after 
transfection, cells were replated as single cells on soft hydrogel (0.7 KPa, soft 
ECM) and, 24 hours after replating, cells were harvested for qPCR analysis. As 
before, the CTGF and PTX3 expression was restored only after depletion of 
ARID1A (Figure 12D and 12E). 
In conclusion, the inhibition of the transcriptional activity of YAP/TAZ 
caused by mechanical regulation can be rescued by ARID1a depletion.  
SWI/SNF complexes work as YAP inhibitors in Neurons 
Next, we wanted to find out the biological relevance of YAP-SWI/SNF 
interaction. YAP is known for its powerful function of growth and tumor 
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promoter. In order to find out the function of SWI/SNF complexes in 
YAP-regulated cell growth, we knockdown the core components of SWI/SNF, 
such as ARID1a, BRG1, BRM or SNF5, and test their influence on BrdU 
incorporation in multiple cell lines: however, we found that loss of SWI/SNF 
component barely change the cell proliferation (data not shown). This result put 
us in the corner and left no option to study SWI/SNF role in YAP-involved 
tumorigenesis. It is broadly accept that two events are very important during 
tumor formation. Aberrant proliferation is for sure important and considered an 
hallmark of cancer, but data from different types of human cancers and mouse 
models at least suggest that acquisition of an immature, stem-like status by 
differentiated cells is a prerequisite for tumor progression. This process is known 
as dedifferentiation. In the ongoing work of our laboratory, we found that 
transient YAP overexpression could reprogram fully differentiated cells back to 
their progenitor cells: this is remarkably true for example in neurons, which can 
be convert to neural stem cells by transient YAP expression. As we identified 
SWI/SNF proteins as inhibitors of YAP/TAZ, we decided to test whether 
YAP-induced neuron-to-NSC dedifferentiation was enhanced by loss of SWI/SNF. 
Following this idea we performed the experiment shown in Figure 13A. 
Hippocampal neurons were derived from late embryos and plated on 
poly-L-lysine pre-coated cell culture plates. Then we first infected neurons with 
tetO-YAP and rtTA-encoding lentiviruses, and selected for mature neurons by 
culturing them in neuronal medium containing the anti-mitotic drug AraC. After 
selection, neurons were infected with shRNA vectors against either BRM or 
ARID1a (knockdown efficiencies were checked in Figure 13D). YAP expression 
was then induced in these cultures by addition of doxycycline in NSC medium. 
Within 15 days of YAP overexpression, neurons lost their morphology and were 
converted to NSC-like cells able to form spherical colonies. As shown in the 
Figure 13B, concomitant knockdown of ARID1a or BRM by shRNA could 
remarkably increase YAP-induced dedifferentiation compare to shRNA control 
(quantifications see Figure 13C) as measured by the increase in the number of 
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initiating spheres. The results showed above imply that SWI/SNF complex works 
as a barrier during YAP-induced reprograming. 
Loss of SWI/SNF complex could help YAP to overcome mechanoregulation   
We next want to investigate if YAP-induced reprogramming of neurons to a 
NSC-like cells was regulated by mechanotransduction through SWI/SNF. To 
answer this question, we plated neurons on top of a Matrigel matrix in order to 
mimic a soft ECM and treated them as above (Figure 14A). Once neurons were 
plated on soft Matrigel (soft ECM), the YAP-induced reprogramming was 
impaired with respect to what happens on a stiff ECM (plastic) (Figure 14B and 
14C): indeed the culture appears as aggregates of neurons expressing the neuronal 
marker NeuN, whereas, on plastic, neurons are converted to SOX2-expressing 
cells by transgenic YAP-expression, that confirmed their transition to a neural 
stem cell-like status (Figure 16). In conclusion, we found that the YAP-induced 
reprogramming of neurons is mechanosensitive and is greatly impaired if neurons 
are plated on a soft ECM. Remarkably, knockdown of SWI/SNF complex 
components Arid1a and Brm could help YAP-induced reprogramming to 
overcome this mechanical regulation (Figure 15B and 15C). Indeed, Arid1a- or 
Brm-depleted neurons greatly shift to a NSC-like status, as, even if plated on top 
of a soft ECM, they start to form spherical aggregates expressing the neural stem 
cell marker SOX2 (Figure 16). 
In conclusion, i) SWI/SNF complexes work as negative regulators during 
YAP-induced reprogramming of neurons. ii) Mechanical regulation could impair 
YAP-induced reprogramming. iii) Depletion of SWI/SNF could release YAP 
from mechanical regulation. 
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DISCUSSION 
 
The data described here presents several elements of novelty. 
1) Nuclear localization of YAP/TAZ does not translate into YAP/TAZ 
activity: need of intra-nuclear activation to turn on YAP/TAZ-dependent 
transcription 
It is generally accepted that YAP/TAZ localization by immunofluorescence 
represents a proxy of their activity. In light of the data here presented, we propose 
that nuclear localization is an obvious prelude to activity, but not a proof of it. 
Indeed, when we enforced YAP/TAZ nuclear localization by LMB, YAP/TAZ 
transcription activity was still inhibited in cells experiencing low mechanical cues 
(such as cells seeded in high confluence or on soft ECM) (Figure 2-4). This 
indicates that mechanotransduction does not end with cytoplasmic F-actin tension 
and organization, but also entails a nuclear step. In other words, different 
mechanosensitive "layers" may exist in cells: some are cytoplasmic and connected 
to organization of the F-actin. An anti-YAP cytoskeleton would include an F-actin 
organization that is very dynamic, generating short fragments by the activity of 
severing proteins and mainly structured as cortical actin layer. Oppositely, a 
cytoplasmic F-actin organization as stress fibers, and actin association to focal 
adhesion and actomyosin contractility represent a pro-YAP conditions. A shift 
from a cytoskeleton that corresponds to a mechanically soft to a stiff condition 
can be induced by attenuation of F-actin regulators, such as cofillin, gelsolin and 
CapZ (Aragona et al., 2013). Yet, even in these conditions nuclear 
mechanotransduction must also occur and entail F-actin regulation of SWI/SNF. 
Nuclear F-actin. Actin is a very abundant protein in the cytosol of 
mammalian cells, but can be also found in the nucleus. In this location, its 
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concentration is lower and confounded by classic cell biology experiments by the 
cytoplasmic staining, which complicates the investigation of its nuclear functions. 
In addition, the control of nuclear actin dynamics is very complex as most actin 
regulators undergo nucleocytoplasmic shuttling in a highly dynamic manner. 
Actin itself is imported and exported by importin 9 and exportin 6 (Dopie et al., 
2012; Stüven et al., 2003). Thus, modulation of nuclear actin is dictated in 
non-obvious ways by F-actin mechanics and organization in the cytoplasm, and 
from availability and shuttling dynamics of its regulators. It is therefore not 
surprising that the formation of nuclear filamentous actin (F-actin) has been 
controversial, up to the point that nuclear actin was considered to be entirely or 
mainly monomeric in its nature. However, several groups demonstrated the 
existence of nuclear F-actin structures in somatic cell nuclei using actin probes of 
high sensitivity ("life-Act"-GFP)(Baarlink et al., 2013; Navarro-Lérida et al., 
2015). It appears that cells possess a rich, extremely dynamic network of F-actin 
and that this can be regulated by serum (a known potent inducer of F-actin 
polymerization in the cytoplasm)(Baarlink et al., 2013) or upon cell spreading on 
a substrate(Plessner et al., 2015). In other words there is a continuum between 
ECM organization and extracellular tension, integrin receptor, cytoplasmic F-actin 
and then nuclear F-actin, perhaps connected through the LINC complex, a 
components of the nuclear lamina bridging the cytoskeleton with the 
nucleoskeleton. Clearly, this cascade, through details that remain to be determined, 
reach YAP/TAZ activity in the nucleus, stabilizing its function.  
 
2) SWI/SNF link nuclear F-actin to YAP/TAZ function. 
In this study, we demonstrated that SWI/SNF complexes bind to YAP 
through YAP WW domain. (Skibinski et al., 2014) suggested already a physical 
association between BRG1 and TAZ. Our studies instead indicate that YAP is 
directly binding to ARID1a but not BRG1 (Figure 9). We thus respectfully 
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suggest that what (Skibinski et al., 2014) were detecting was an indirect 
association between BRG1 and TAZ, likely mediated by ARID1a. Alternatively, 
it is also possible that YAP and TAZ may associate to the SWI/SNF complex 
through distinct mechanisms. In most assays, in fact, YAP and TAZ are 
functionally identical and typically redundant with each other by loss-of-function. 
That said, they are also highly related but not absolutely identical proteins and 
their individual germ-line knockout phenotype at least indicate an earlier and 
more profound, essential requirement of YAP during embryogenesis. This is to 
say that it might not be surprising that YAP/TAZ would display different 
mechanisms of regulation. 
An important discovery here is that SWI/SNF complexes are YAP/TAZ 
inhibitors inside the nucleus (Figure 6 and 7). This was shown first in cell lines, 
using MCF10A and HEK293 cells. Loss of SWI/SNF components in these cells 
causes increased activity of YAP/TAZ endogenous targets and luciferase 
TEAD/YAP/TAZ-artificial sensors. This indicated that SWI/SNF are buffering 
YAP/TAZ activity. 
This discovery represents a novelty in the epigenetic field. SWI/SNF are in 
textbooks of molecular biology because of their ability to mobilize nucleosomes 
and remodel chromatin by utilizing the energy of ATP hydrolysis (Kassabov et al., 
2003; Phelan et al., 1999). These 2 MDa complexes are made up of 12–15 
subunits. Some core subunits are present in all SWI/SNF complexes, including 
SNF5 (or SMARCB1/INI1/BAF47), SMARCC1 (BAF155) one of the catalytic 
ATPase subunit, either BRG1 (SMARCA4) or BRM (SMARCA2). In addition, 
there are subunits present only in some variants, such as ARID1A and ARID1B, 
that are mutually exclusive subunits for BAF complexes, and PBRM1 and ARID2, 
specific for PBAF complexes (Figure 1A) (Wang et al., 1996; Wu et al., 2009). 
Here we found that ARID1a serves as bridge between YAP and SWI/SNF. In 
preliminary results not shown here, we failed to detect similar functions by 
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ARID1b, limiting the possibility of a functional redundancy. The composition of 
SWI/SNF complexes in time, space and cell type is a mystery. In light of the 
rather specific role of ARID1a as YAP inhibitor, ARID1a function as leading 
tumor suppressor and of the role of YAP during cancer and tissue repair, it would 
be tempting to propose that ARID1a may be a facultative components recruited to 
SWI/SNF complexes under some form of tissue stress or when tissues need to 
cope with rapid growth. 
3) A mechanisms for SWI/SNF tumor suppressive effects 
As introduced, 20% of all human tumors present inactivating mutations in 
SWI/SNF components. ARID1a is particularly prominent in these lists being 
mutated (loss of function) in 45% of ovarian clear cell and endometrioid 
carcinomas (Jones et al., 2010); 19% of bladder cancers; 19% of gastric cancers; 
14% of hepatocellular cancers; 12% of melanomas; and also less frequently in 
lung, breast, colorectal, pancreas, and several other types of cancer (summarized 
in (Helming et al., 2014)). The function of mutated SWI/SNF complexes in cancer 
and the mechanisms! by! which! mutations in individual subunits promote 
oncogenesis are now active areas of research.  
When we initiated these studies, our first assays for SWI/SNF have been cell 
proliferation assays. Overall we got disappointing results: loss of SWI/SNF is 
either detrimental for cell survival or dispensable. This is apparently at odd with 
their role as tumor suppression, but in line with their well-established and 
fundamental determinants of chromatin biology. Clearly the sophistication of 
SWI/SNF composition (presence or absence of facultative components, also 
keeping in mind that BRG1 and BRM are invariably kept as separate entities) 
allows cells to display a great plasticity: the possibility to use one subtype for one 
fundamental function (i.e. nucleosome remodeling) and the other for other, 
perhaps more sophisticated and unknown tumor suppressing functions. In turn 
"tumor suppression" is word for a generic concept not automatically connected to 
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the control of cell proliferation. In several cell lines, we were initially discouraged 
by finding that ARID1a inactivation was actually inconsequential for cell 
proliferation (by BrDU incorporation and Ki67 stainings). This prompted us to 
search for a function of ARID1a connected to different functions of YAP/TAZ 
also unrelated to cell growth per se. Instead, our data seem to suggest that 
SWI/SNF are tumor suppressors because they inhibit YAP/TAZ-induced cell 
dedifferentiation. Thus growth and dedifferentiation represent different entities, 
potentially controlled by different SWI/SNF complex. See point 4 of this 
discussion.  
Future perspective. To gain insight this problem, for the future, we plan to 
carry out in vivo experiments using established mouse models either of 
tumorigenesis or dedifferentiation. To test whether YAP/TAZ activity is in fact 
downstream of SWI/SNF inactivation, we will cross LOX-STOP-LOX 
KRasG12V; Arid1a -/+ mice, with YAP/TAZ conditional alleles under the control 
of the K14-CreERT2 and K8-CreERT2 drivers, mediating deletion in the basal 
and luminal compartments of the mammary gland, respectively (van Keymeulen 
et al, 2015). With these experiments, we will test if loss of YAP/TAZ (in either 
compartments) rescues tumor suppression in the ARID1a mutant background; or 
if their loss in already established, fully grown mammary gland tumors (by timing 
tamoxifen addition) enhances their differentiation (as monitored by histology 
and/or FACS profile), and is accompanied by the loss of prospective cancer SCs 
(as validated by the mammosphere self-renewal assay). In a complementary 
approach, we will address the requirement of SWI/SNF complexes for YAP/TAZ 
dependent acquisition of cancer SC properties by non-CSCs. For this, we will 
evaluate the acquisition of self-renewal and tumorigenic potential of mammary 
cells after TAZ overexpression (or endogenous TAZ activation by EMT) and 
depletion of ARID1a, BRG1 and/or BRM. 
4) YAP/TAZ induced reprogramming is regulated by mechanical cues. 
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 In an independent research line of our lab, we found that ectopic expression 
of YAP in terminally differentiated cells, such as primary neurons, can trigger 
their dedifferentiation and acquisition of stem cells traits (this work is currently 
submitted as Panciera et al.). In this thesis, we took advantage of these studies and 
used YAP-induced cell dedifferentiation of neurons into NSCs as a playground to 
study: A) the role of mechanical signals as essential for cell reprogramming and 
somatic SC acquisition, demonstrating that a pliant, soft ECM microenvironment 
preserves cell differentiation, blunting the effect of YAP overexpression; and B) 
the role of ARID1a (and Swi/SNF more in general) as factors involved in 
preserving cell differentiation on pliant ECMs. Mechanistically, this is mediated 
by SWI/SNF serving as a mechanosensors: the complex indeed seems to bind to 
YAP through the ARID1a bridge in soft cells and in a mutually exclusive manner 
to F-actin. In soft and stiff cells SWI/SNF complex thus appear to change its 
composition: from a SWI/SNF/ARID1a-YAP/TAZ in soft cells to a 
SWI/SNF/F-actin in stiff cells. In soft cells, a SWI/SNF/ARID1a-YAP/TAZ 
complex prevents YAP/TAZ activity on target in primary cells. This gatekeeper 
function is surpassed once the complex switches to a SWI/SNF/F-actin mode, 
setting free YAP and as such unleashing its de-differentiation and, at least in 
cancer, tumor progressive functions. Our results have thus far reaching 
implications. Finding that a transient exposure to YAP and TAZ is sufficient to 
rewire the genome of fully differentiated cells into multipotent SC-like cells bears 
profound implications for cancer biology. Cancer is a disease of disturbed cell 
differentiation as much as it is of aberrant cell proliferation. In the past 30 years, 
emphasis has been placed on oncogenic regulation of tumor growth (Hanahan and 
Weinberg, 2011). Data from different types of human cancer and mouse models at 
least suggest that acquisition of an immature, stem-like state is a prerequisite for 
tumor progression(Hanahan and Weinberg, 2011). This issue obviously connects 
with another fundamental question, that is, what is the cancer cell of origin. In one 
scenario, oncogenes may hit normal tissue SCs that already possess the 
self-renewal and differentiation capacities normally used for tissue replenishment. 
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An alternative (although not mutually exclusive) scenario is that tumor cells may 
be generated de novo from more differentiated healthy/normal cells. Indeed, 
activation of RasG12V combined with loss-of-p53 has been shown to readily 
reprogram terminally differentiated neurons into glioma-SCs 
(Friedmann-Morvinski et al., 2012); and RasG12V combined with loss-of-APC 
induced differentiated intestinal cells to become tumor initiating cells (Schwitalla 
et al., 2013). It is thus possible that, at their incipit, oncogenic lesions may first 
promote the generation of de-differentiated cellular states that are permissive for 
proliferation and self-renewal. In vivo, cells emerging from this 
oncogene-mediated reprogramming may be restrained by the normal tissue 
context. The persistence of this state coupled with other genetic, epigenetic and 
environmental alterations such as a raise in the architecture or rigidity of the 
environement may allow a second phenotypic switch, that is, transition to a tumor 
initiating cell whose self-renewal has become unresponsive to the tumor 
suppressive tissue context.  
Future perspectives. Tumor progression is frequently accompanied by an 
increase in stem cell representation (Di Fiore Pece) within the tumor, by ARID1a 
mutations and by a raise in YAP/TAZ activity. As discussed above, our results 
provide a mechanism that connected these events. It will be now important to test 
whether loss of ARID1a causes breast cancer cells to switch to a more 
undifferentiated cancer-stem-cell-like status, phenocopying earlier results 
obtained with TAZ or YAP overexpression. 
It will be also important to test whether somatic cell reprogramming induced 
by expression of ectopic YAP/TAZ does reflect in a similar relevance of 
endogenous YAP/TAZ during dedifferentiation occurring in vivo during 
tumorigenesis induced in neurons by common oncogenic lesions such as PDGF 
overexpression, loss of p53 or activation of Ras mutations. It will be important to 
combine this with mouse mutants for YAP/TAZ to test if these events are 
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addicted to YAP/TAZ and whether a sufficient cell mechanics is involved and 
permissive for dedifferentiation to a somatic SC status by cancer cells.  
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 EXPERIMENTAL PROCEDURES 
 
Reagents and plasmids 
Latrunculin A, Leptomycin B and phalloidin were from Sigma. Doxycycline 
was from Calbiochem. Matrigel was from BD. 
pCDNA3 FLAG-hYAP1 WT and FLAG-hYAP1 5SA were generated by 
PCR from original HA-tagged cDNAs kindly provided by Dr. Guan, made 
insensitive to YAP siRNA#1 and siRNA#2 by point mutagenesis (Dupont et al., 
2011) and subcloned in pBABE retroviral plasmids to establish stable cell-lines. 
pBABE-Hygro empty vector was used as control retroviral transduction. For YAP 
structure function studies of Figure 10, deletion constructs of Flag-hYAP1 were 
generated by PCR. Flag-YAP WW mut were introduced mutations (Tryptophan 
258 to Alanine and Proline 261 to Alanine) into pCDNA3 FLAG-hYAP1. 
Flag-YAP S94A was generated by site-specific PCR mutagenesis. For inducible 
expression in mouse neurons, YAP WT was subcloned in a doxycycline-inducible 
lentiviral expression vector (Fu-tetON, Cordenonsi et al, 2011). The 8xGTIIC-lux 
(Dupont et al., 2011) is (Addgene #34615). pCS2 Flag-BRM was obtained by 
subcloning Flag-BRM from pBABEpuro Flag-BRM (Addgene #1961) into pCS2. 
pCS2 Flag-BRG1 was obtained by subcloning Flag-BRG1 from pBABEpuro 
Flag-BRG1 (Addgene #1957) into pCS2; Flag-BRG1 ΔHSA was generated by 
PCR by deleting HSA domain (deletion of residues 462-532). The constructs for 
shControl, shArid1a, and  shBrm expression in primary neurons were prepared 
by cloning the Control, mouse siARID1A#1, mouse siARID1A#2, mouse 
siBRM#1 and mouse siBRM#2 sequences (see RNAi section) into pLKO.1-puro 
lentiviral vector (Addgene #8453;Stewart et al. 2003)) according to 
manufacturer’s protocol. 
All constructs were confirmed by sequencing. 
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Cell lines and treatments 
MII cells were a gift from S. Santner (Santner et al., 2001). MCF10A and MII 
cells were cultured in DMEM/F12 (Gibco, Life Technologies) with 5% horse 
serum (HS), glutamine and antibiotics, freshly supplemented with insulin, EGF, 
hydrocortisone, and cholera toxin. HEK293 and HEK293T cells were cultured in 
DMEM (Gibco, Life Technologies) supplemented with 10% fetal bovine serum 
(FBS), glutamine and antibiotics. 
Cells plated on plastic are considered as cultured on a stiff ECM. For experiments 
on soft ECM, 5,000–10,000 cells per cm2 were seeded in drop on top of 0.7 kPa 
hydrogels; after attachment, the wells containing the hydrogels were filled with 
appropriate medium. Cells were then harvested for immunofluorescence or RNA 
extraction after 24 hours. For experiments with higly confluent cells, we plated 
200000 cells per cm2 in the appropriate well; after attachment, the wells filled 
with medium. Cells were then harvested for immunofluorescence or RNA 
extraction after 24 hours. 
Latrunculin A was used at a final concentration of 0.5 µM for the time indicated 
in the text. LMB was incubated at a final concentration of 15 ng/ml for the last 
two hours of the indicated experiments. 
 
RNA interference 
siRNA transfections were done with Lipofectamine RNAi-MAX (Life 
technologies) in antibiotics-free medium according to manufacturer instructions. 
Sequences of siRNAs are provided in Table 3. 
 
Western blot 
Cells were harvested by sonication and extracts quantified with Bradford 
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method. Proteins were run in 4-12% Nupage-MOPS acrylamide gels and 
transferred onto PVDF membranes by wet electrophoretic transfer. Blots were 
blocked with non-fat dry milk and incubated overnight at 4°C with primary 
antibodies. Secondary antibodies were incubated 1 hr at room temperature, and 
then blots were developed with chemiluminescent reagents. Images were acquired 
with Image Quant LAS 4000 (GE healthcare). 
For Western blot: anti-YAP/TAZ, anti-BAF53a, anti-BRG1, anti-SMARCC1, 
anti-PTPN14, anti-TEAD4, anti-AMOT, anti-Gelsolin (GSN) were from Santa 
Cruz. anti-LATS1 was from CST. anti-ARID1A and anti-SNF5 were Sigma. 
anti-YAP and anti-BRM were from Abcam. anti-TEAD1 was from BD. 
anti-Actin was from Cytoskeleton. anti-GAPDH monoclonal antibody was from 
Millipore.  Horseradish-peroxidase-conjugated anti-Flag (clone M2, A8592) was 
from Sigma and the anti-HA (A190-107P) was from Bethyl. 
 
Luciferase Assays  
Luciferase assays were performed in HEK293 cells with the established 
YAP/TAZ-responsive luciferase reporter 8xGTIIC-Lux (Dupont et al., 2011). 
8xGTIIC-Lux reporter (50 ng/cm2) were transfected together with CMV-β-gal (75 
ng/cm2) to normalize for transfection efficiency with CPRG (Roche) colorimetic 
assay. DNA transfections were done with TransitLT1 (Mirus Bio) according to 
manufacturer instructions. DNA content in all samples was kept uniform by 
adding pBluescript plasmid up to 250 ng/cm2. In experiments in siRNA-depleted 
cells (Figure 7), cells were first transfected with the indicated siRNAs and, the 
day after, washed from transfection media, transfected with plasmid DNA, and 
harvested 48 hr later. Each sample was transfected in duplicate and each 
experiment was repeated at least three times independently. 
 
Quantitative Real-Time PCR 
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Cells were harvested by RNeasy Mini Kit (Quiagen) for total RNA 
extraction, and contaminant DNA was removed by DNase treatment. qRT-PCR 
analyses were carried out on retrotranscribed cDNAs with Rotor-Gene Q thermal 
cycler (Quiagen) and analyzed with Rotor-Gene Analysis 6.1 software. 
Experiments were performed at least three times, with duplicate replicates. 
Expression levels are always given relative to GAPDH. PCR oligo sequences are 
listed in Table 1. 
 
F-actin pulldown 
For the experiments depicted in Figure 11B, cells were plated in sparse 
conditions and either left untreated or treated for 4 hours with Lat.A (LatA for this 
sample condition was kept also in the following buffers used for harvesting and 
immunoprecipitation). Cells were then harvested in Actin lysis buffer (20 mM 
HEPES (pH 7.8), 50 mM KCl, 0.1% Triton, 5% Glycine, 0.1% NP40, 5 mM 
MgCl2, 1 µM DTT, MG105/MG132, phosphatase and protease inhibitors) 
containing Biotinilated-Phalloidin (Sigma) and mechanically disrupted. Extracts 
were cleared by centrifugation and incubated at room temperature for three hours 
streptavidin-coniugated resin (Sigma). Phalloidin complexes were then washed 
with Actin lysis buffer three times at room temperature resuspended in SDS 
sample buffer, and subjected to SDS-PAGE and Western blot analysis. 
 
Coimmunoprecipitation of Endogenous proteins 
For immunoprecipitations of endogenous proteins of Figures 8D and 9A, 
Cells were harvested and lysed by sonication in Lysis Buffer (50 mM HEPES (pH 
7.8), 100 mM NaCl, 50 mM KCl, 1% Triton, 5% Glycine, 0.5% NP40, 2 mM 
MgCl2, 1 µM DTT, phosphatase and protease inhibitors) and cleared by 
centrifugation. 
Extracts were incubated with anti-ARID1A (Santa Cruz) antibody or control 
rabbit IgG immobilized on Protein G-Sepharose beads at 4°C overnight. 
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Immunocomplexes were then washed with cold Lysis buffer three times, 
resuspended in SDS sample buffer, and subjected to SDS-PAGE and Western blot 
analysis. 
For the experiments depicted in Figures 11C and D, cells were plated in 
sparse conditions and treated for 4 hours with either Phalloidin or Lat.A. For 
Phalloidin-treated samples, Phalloidin was kept also in the following buffers used 
for harvesting and immunoprecipitation. For Lat.A-treated samples, Lat.A was 
kept also in the following buffers used for harvesting and immunoprecipitation). 
Cells were then harvested in Actin lysis buffer and mechanically disrupted. 
Extracts were cleared by centrifugation and incubated with anti-YAP (Abcam) 
antibody or control rabbit IgG immobilized on Protein G-Sepharose beads at 4°C 
overnight. Immunocomplexes were then washed with Actin lysis buffer three 
times, resuspended in SDS sample buffer, and subjected to SDS-PAGE and 
Western blot analysis. 
 
Coimmunoprecipitation of Tagged proteins 
Cells were transfected with the indicated plasmids; after 48 hours, cells were 
harvested and lysed by sonication in Lysis Buffer (50 mM HEPES (pH 7.8), 100 
mM NaCl, 50 mM KCl, 1% Triton, 5% Glycine, 0.5% NP40, 2 mM MgCl2, 1 µM 
DTT, phosphatase and protease inhibitors). Extracts were incubated three hours at 
4°C with anti-Flag resin (Sigma). Immunocomplexes were then washed with cold 
Lysis buffer three times, resuspended in SDS sample buffer, and subjected to 
SDS-PAGE and Western blot analysis. Inputs were loaded according to Bradford.  
 
Mass Spectroscopy 
Eluates from immunoprecipitations described in Figure 5 were run in a 4-12% 
gradient SDS-Page acrylamide gel and the gel was sent to the EMBL core 
proteomic facility for MS analysis. Each sample lane was cut into five pieces 
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according to molecular weight, and all the proteins contained in each piece 
subjected to in-gel tryptic digestion. The resulting peptides were purified and 
subjected to identification based on their mass according to EMBL parameters. 
 
Immunofluorescence 
    Cells were fixed 10 min at room temperature (RT) with PFA 4%. Slides were 
permeabilized 10 min at RT with PBS 0.3% Triton X-100, and processed for 
immunofluorescence according to the following conditions: blocking in Goat 
Serum (GS, 10%) in PBST for 1.5 hr, followed by incubation with primary 
antibodies (diluted in 2% GS in PBST) for 16 hr at 4°C, four washes in PBST and 
incubation with secondary antibodies (diluted in 2% GS in PBST) for 1.5 hr at 
room temperature. After three washes in PBS, nuclei were stained with ProLong 
DAPI (Life Technologies). Primary antibodies are: anti-YAP/TAZ (Santa Cruz), 
anti-NeuN (Abcam), anti-SOX2 (CST). Secondary antibodies (1:200; Invitrogen) 
are: goat anti-mouse Alexa568, goat anti-rabbit Alexa488, goat anti-mouse647. 
When indicated, Alexa488-conjugated phalloidin (Life Technologies) was used 
1:200 during secondary antibodies incubation to visualize F-actin microfilaments. 
Confocal images were obtained with a Leica TCS SP5 equipped with a CCD 
camera. 
Immunofluorescence on matrigel 
    Cells were fixed with 4% PFA at room temperature for 24 h. The fixed cells 
were then permeabilized with PBS 0.3% Triton X-100 and blocked by incubating 
with a blocking solution containing 50 mM Tris (pH7.4), 0.1% Tween-20, 10% 
GS, 1% BSA, and 0.3 M glycine at 4°C for 12 h. After washing with TBS 
containing 0.1% (v/v) Triton X-100 (TBST), the 3D cultures were incubated with 
primary antibodies in the blocking solution at 4°C for 24 h. After washing five 
times with TBST (each time 1 hour at 4 °C), cells were further incubated with 
AlexaFluor secondary antibodies (LifeTechnologies) overnight at 4 °C. After 
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three washes in TBST, nuclei were stained with ProLong DAPI (Life 
Technologies). Confocal images were obtained with a Leica TCS SP5equipped 
with a CCD camera. 
Lentivirus preparation 
HEK293T cells (checked routinely for absence of mycoplasma 
contaminations) were kept in DMEM supplemented with 10% FBS (Life 
Technologies), Glutamine and Antibiotics (HEK medium). Lentiviral particles 
were prepared by transiently transfecting HEK293T with lentiviral vectors (10 
micrograms/10 cm dishes) together with packaging vectors pMD2-VSVG (2.5 
micrograms) and pPAX2 (7.5 micrograms) by using TransIT-LT1 (Mirus Bio) 
according to manufacturer instructions.  
 
Primary neuron isolation, infection and culturing  
Neurons were prepared from hippocampi of E18-19 wild-type embryos. 
Briefly, hippocampi were dissected under the microscope in ice cold HBSS as 
quick as possible, incubated with 0.05% trypsin (Life Technologies) 15 min at 
37°C and, after trypsin blocking, resuspended in DMEM/10% FBS supplemented 
with 0.1 mg/ml DNase I (Roche), and mechanically dissociated by extensive 
pipetting. Cells were then plated on poly-L-lysine-coated wells (stiff conditions) 
or on top of a Matrigel layer (soft conditions) in DMEM supplemented with 10% 
FBS, glutamine and antibiotics for hippocampal neurons, or in 
DMEM/Neurobasal (1:1) supplemented with 5% FBS, 1x B27, glutamine and 
antibiotics for cortical neurons (day 1). After 24 hours (day 2), the medium of 
hippocampal preparation was changed to fresh DMEM/Neurobasal (1:1) 
supplemented with 5% FBS, 1X B27, glutamine and antibiotics. For 
reprogramming experiments neurons were infected on the following day (day 3) 
with FUW-tetO-wtYAP and FUdeltaGW-rtTA viral supernatants. Negative 
controls were provided by neurons transduced with FUdeltaGW-rtTA alone or in 
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combination with FUW-tetO-EGFP. After 24 hour (day 4), medium was changed 
and cells were incubated in Neurobasal medium supplemented with 1X B27, 
glutamine, antibiotics, and 5 µM Ara-C (cytosine β-D-arabinofuranoside; Sigma) 
for additional 7 days, at the end of which well-differentiated, complex 
network-forming neurons are visible. Then, neurons were infected with 
pLKO.1-shRNA as indicated and negative control was shCO. For this for a 
typical 3.5 cm plate, we mixed 500 µl of PLKO.1-shRNA produced in NSC 
medium (DMEM/F12 supplemented with 1X N2, 20 ng/ml murine EGF, 20 ng/ml 
murine bFGF, glutamine, and antibiotics) and 1.5 ml of serum-free Neurobasal 
medium with 1X B27. Treated neurons were switched to NSC medium and 2 
µg/ml doxycycline for activating tetracycline-inducible gene expression. After 7 
days, fresh doxycycline (final concentration of 2 µg/ml) was added. Sphere 
formation was evident upon YAP induction after 14 days of doxycycline 
treatment.  
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Table 1. PCR oligo sequences. Related to Experimental Procedures. 
 
Gene Forward primer Reverse primer 
human     
GAPDH AGCCACATCGCTCAGACAC  GCCCAATACGACCAAATCC 
ANKRD1 AGTAGAGGAACTGGTCACTGG TGGGCTAGAAGTGTCTTCAGAT  
PTX3 TGCATCTCCTTGCGATTCTG GAGCTTGTCCCATTCCGAGT 
CYR61: CCTTGTGGACAGCCAGTGTA ACTTGGGCCGGTATTTCTTC 
CTGF AGGAGTGGGTGTGTGACGA  CCAGGCAGTTGGCTCTAATC 
ARID1a GGGGCGCCTCCTCACT CTTTGTTGTCCGCCATGTTG 
BRG1 CGCATTCGCAACCACAAGTA CCTCACTCTCCTCGCCTTCA 
BRM CCCCCAAACTGACAAAGCAG CTGAGCTGTCGCCCTGAACT 
mouse     
Gapdh ATCCTGCACCACCAACTGCT GGGCCATCCACAGTCTTCTG 
Arid1a TGAAAGACATTGGAACCCCG TCTAGCAAGCCTGGGAGCTG 
Brm ATCTTCAGGCGGCAGACACG ATCTTCAGGCGGCAGACACG 
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Table 2. RNAi sequences. Related to Experimental Procedures. 
!
siRNA/ shRNA Interfering sequence (target) 
Control#1 AllStars Negative Control siRNA (QIAGEN) 
Control#2 TTCTCCGAACGTGTCACGT 
human   
ARID1a#1 GGCGGGAACTTGCAACCAA 
ARID1a#2 CGGTATCACCGTTGATGAA 
BRG1#1 GCGCTACAACCAGATGAAA 
BRG1#2 ACTGGATGTCAAACAGTAA 
BRM#1 GCGTCTACATAAGGTGTTA 
BRM#2 CCGCATAGCTCATAGGATA 
YAP#1 GACATCTTCTGGTCAGAGA 
YAP#2 CTGGTCAGAGATACTTCTT 
TAZ#1 ACGTTGACTTAGGAACTTT 
TAZ#2 AGGTACTTCCTCAATCACA 
LATS1 CACGGCAAGATAGCATGGA 
LATS2 AAAGGCGTATGGCGAGTAG 
mouse 
Arid1a#5 CACCATTAACATTCTACTGTA 
Arid1a#6 CACGTGTTAAGAATAAATGTA 
Brm#1 CAGGAAAGACTTACCAGAATA 
Brm#2 TACCAGAATACTATGAATTAA ! !
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Table 3. Some positive results of MS !
  
untreated untreated Lat.A Lat.A 
Accession Number MW - Flag-YAP-5SA Flag-YAP -5SA - 
TEAD1_HUMAN 48 kDa 0 6 4 0 
TEAD2_HUMAN 49 kDa 0 1 1 0 
TEAD3_HUMAN 49 kDa 0 16 9 0 
TEAD4_HUMAN 48 kDa 0 4 1 0 
LATS1_HUMAN 127 kDa 0 17 29 0 
LATS2_HUMAN 120 kDa 0 6 15 0 
ZYX_HUMAN 61 kDa 0 2 2 0 
MPDZ_HUMAN 222 kDa 0 19 52 0 
PTN14_HUMAN 135 kDa 0 29 62 0 
WWC2_HUMAN 134 kDa 0 1 4 0 
WWC3_HUMAN 123 kDa 0 9 13 0 
CTNA1_HUMAN 100 kDa 1 1 0 3 
ZO1_HUMAN 195 kDa 0 0 3 0 
ZO2_HUMAN 134 kDa 0 1 5 0 
INADL_HUMAN 196 kDa 0 23 41 0 
LIN7C_HUMAN 22 kDa 0 4 5 0 
MERL_HUMAN 70 kDa 0 21 27 0 
MPP5_HUMAN 77 kDa 0 9 27 0 
AMOL1_HUMAN 107 kDa 0 30 30 0 
AMOL2_HUMAN 86 kDa 0 44 68 0 
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Table 4. Results of MS 
 
  
untreated untreated Lat.A Lat.A 
Accession Number MW - Flag-YAP-5SA Flag-YAP -5SA - 
ARID1A_HUMAN 242 kDa 0 4 11 0 
ARID1B_HUMAN 236 kDa 0 0 4 0 
BRG1_HUMAN 185 kDa 0 2 10 0 
SMARCC1_HUMAN 123 kDa 0 1 8 0 
BAF53a_HUMAN 47 kDa 0 3 1 0 
SMARCA5_HUMAN 122 kDa 0 1 2 0 
PARD3_HUMAN 151 kDa 0 0 8 0 
RPGF6_HUMAN 179 kDa 0 0 7 0 
EZRI_HUMAN 69 kDa 0 0 4 0 
UBA1_HUMAN 118 kDa 0 0 4 0 
CTRO_HUMAN 231 kDa 0 0 3 0 
CKAP4_HUMAN 66 kDa 0 0 3 0 
RASF8_HUMAN 48 kDa 0 0 2 0 
ARHG2_HUMAN 112 kDa 0 0 2 0 
CAP1_HUMAN 52 kDa 0 1 2 1 
TPPC9_HUMAN 129 kDa 0 0 2 0 
IF4G1_HUMAN 175 kDa 0 0 2 0 
C1TM_HUMAN 106 kDa 0 0 2 0 
TET2_HUMAN 224 kDa 0 0 2 0 
E2F7_HUMAN 100 kDa 0 0 2 0 
EMD_HUMAN 29 kDa 0 0 2 0 
HMHA1_HUMAN 125 kDa 0 0 2 0 
HNRL1_HUMAN 96 kDa 0 0 2 0 
MCM2_HUMAN 102 kDa 0 0 2 0 
MSH6_HUMAN 153 kDa 0 0 2 0 
RNC_HUMAN 159 kDa 0 0 2 0 
STAT1_HUMAN 87 kDa 0 0 2 0 
XRCC5_HUMAN 83 kDa 0  29  38  0  
XRCC6_HUMAN 70 kDa 0  34  36  2  
MYH9_HUMAN 227 kDa 3  22  33  2  
ANM5_HUMAN 73 kDa 3  12  15  1  
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Figure 1. Introduction 
A. Schematic representation of the Hippo pathway. 
B. Schematic representation of how mechanic cues regulate YAP/TAZ 
C. Schematic representation of YAP induced reprogramming. 
D. Schematic representation of SWI/SNF complexes. 
Figure 1
A
B
C
D
! 70!
Figure 2. Treatment with Latrunculin A in sparse epithelial mammary cells 
causes YAP/TAZ transcriptional inhibition that can not be rescued by 
blocking YAP/TAZ nuclear export  
A. Schematic representation of the experimental procedure. MCF10A cells were 
plated at low confluence (sparse) and, after attachment, treated with Latrunculin 
(Lat.A; 0.5 µM) and Leptomycin B (LMB; 15 ng/mL) as indicated, and then fixed 
for immunofluorescence or harvested for RNA extraction.  
B. MCF10A cells were treated as in A and stained for immunofluorescence with 
anti-YAP/TAZ antibody. Phalloidin shows cell border and the effect of Lat.A. 
Nuclei were couterstained with DAPI.  
C. Quantifications of Figure 2B. The panel shows the proportion of cells 
displaying: N+N/C, nuclear YAP/TAZ localization or even distribution in the 
nucleus and cytosol; or C, cytosol YAP/TAZ localization.  
D. MCF10A cells were treated as in A and harvested for RNA extraction. Panels 
are qRT-PCR results for CYR61 and ANKRD1, expression normalized to GAPDH 
expression. Data are normalized to untreated cells and presented as mean + SD. 
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Figure 3. High cell densitiy leads to YAP/TAZ transcriptional inhibition that 
can not be rescued by blocking YAP/TAZ nuclear export  
A. Schematic representation of the experimental procedure. MCF10A cells were 
plated at high confluence (dense) and, after 24 hours, treated with LMB, as 
indicated, and then fixed for immunofluorescence or harvested for RNA 
extraction.  
B. MCF10A cells were treated as in A and stained for immunofluorescence with 
anti-YAP/TAZ antibody. Nuclei were couterstained with DAPI.  
C. Quantifications of Figure 3B. The panel shows the proportion of cells 
displaying: N+N/C, nuclear YAP/TAZ localization or even distribution in the 
nucleus and cytosol; or C, cytosol YAP/TAZ localization.  
D. MCF10A cells were treated as in A and harvested for RNA extraction. Panels 
are qRT-PCR results for CYR61 and PTX3 expression, normalized to GAPDH 
expression. Data are normalized to sparse cells and presented as mean + SD. 
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Figure 4. A soft ECM leads to YAP/TAZ transcriptional inhibition that can 
not be rescued by blocking YAP/TAZ nuclear export  
A. Schematic representation of the experimental procedure. MCF10A cells were 
plated either on plastic (stiff) or on a soft ECM (hydrogel 0.7 kPa). After 24 hours, 
cells were treated with LMB, as indicated, and then fixed for immunofluorescence 
or harvested for RNA extraction.  
B. MCF10A cells were treated as in A and stained for immunofluorescence with 
anti-YAP/TAZ antibody. Nuclei were couterstained with DAPI.  
C. Quantifications of Figure 4B. The panel shows the proportion of cells 
displaying: N+N/C, nuclear YAP/TAZ localization or even distribution in the 
nucleus and cytosol; or C, cytosol YAP/TAZ localization.  
D. MCF10A cells were treated as in A and harvested for RNA extraction. Panels 
are qRT-PCR results for CYR61 and PTX3 expression, normalized to GAPDH 
expression. Data are normalized to cells plated on a stiff ECM (plastic) and 
presented as mean + SD. 
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Figure 5. Biochemical screening the YAP/TAZ interactors 
AScheme of the working hypothesis on the mediator of effect of F-actin and 
YAP/TAZ. Two hypotheses may explain the regulation of YAP/TAZ by 
mechanical cues: i) the existence of a protein X activated by intact F-actin and 
required to sustain YAP/TAZ function; the interaction between YAP and protein 
X is expected to decrease upon F-actin disassembly (i.e. Lat.A treatment); or ii) 
the existence of protein Y inhibited by F-actin and usually functioning as a natural 
inhibitor of YAP/TAZ; the interaction between YAP and protein Y therefore is 
expected to be stabilized by disruption of the F-actin cytoskeleton. 
B. Silver stain gel of proteins after immunoprecipitation with anti- Flag 
antibody in MCF10A cells stably-expressing Flag-tagged YAP 5SA or and 
MCF10A cells transduced with empty vector as a (negative) control, treated with 
Lat.A as indicated. The gel was sent to the EMBL core proteomic facility for 
mass spectroscopy analysis. 
C. Validation of our immunoprecipitation experimental set-up described in Figure 
5B. TEAD1, AMOTL2 and LATS were correctly found in the 
Flag-immunoprecipitation MCF10A cells stably-expressing Flag-tagged YAP 
5SA . 
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Figure 6. Screening of MS results: SWI/SNF complexes work as YAP/TAZ 
inhibitors 
A. qRT-PCR for YAP/TAZ target gene CTGF, normalized to GAPDH expression, 
in MCF10A cells transfected with control, ARID1A or SNF5 siRNAs as indicated. 
Data are normalized to control siRNA-treated cells and presented as mean + SD.  
B. and C. ARID1A- and SNF5-siRNAs (used in the Figure 6A) knockdown 
efficiencies were checked by qRT-PCR. ARID1a and SNF5 expression levels are 
relative to GAPDH expression. 
D. qRT-PCR for CTGF, normalized to GAPDH expression, in MCF10A cells 
transfected with control or BRG/BRM siRNAs as indicated. Data are normalized 
to control siRNA-treated cells and presented as mean + SD. 
 
E. and F. BRG1- and BRM-siRNA (used in the Figure 6D) knockdown 
efficiencies were checked by qRT-PCR. BRG1 and BRM expression level are 
relative to GAPDH expression. 
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Figure 7. Loss of SWI/SNF complex components activate a synthetic TEAD 
reporter in a YAP/TAZ-dependent manner. 
A. and B. HEK293 cells were left untreated (UNT) or transfected with indicated 
siRNAs to deplete the endogenous genes. The panels represent the results of 
luciferase assays with the 8xGTIIC-Lux reporter, recording YAP/TAZ-dependent 
transcriptional activity. Data are normalized to UNT and are presented as mean + 
SD. 
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Figure 8. YAP interacts with SWI/SNF complex. 
A. HEK293T cells were transfected with Flag-tagged BRM and HA-YAP 5SA. 
Lysates of these cells were subjected to anti-Flag immunoprecipitation and 
co-precipitating proteins were visualized by western blot (upper panel). The inputs 
were also checked by western blot (Lower panel).  
B. HEK293T cells were transfected with HA-YAP 5SA and Flag-BRG1, either 
wild type or deleted of the HSA domain (ΔHSA). Lysates of these cells were 
subjected to anti-Flag immunoprecipitation and co-precipitating proteins were 
visualized by western blot (upper panel). The inputs were also checked by western 
blot (Lower panel). 
C. MCF10A cells were stably transduced with Flag-YAP 5SA or with the 
corresponding empty vector (negative control). Lysates of these cells were 
subjected to anti-Flag immunoprecipitation and co-precipitating proteins were 
visualized by western blot. 
D. Lysates from MII cells were subjected to immunoprecipitation using an 
anti-ARID1A antibody or rabbit IgG as control. Co-precipitating endogenous 
proteins were visualized by Western blot. 
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Figure 9. YAP directly binds to ARID1a. 
A. HEK293T cells were transfected with two independent control siRNAs (lanes 
1, 2 and lanes 3, 4) or with mixed siRNAs against BRG1 and BRM (lanes 5, 6). 
Lysates of these cells were subjected to IP using an anti-ARID1a antibody or 
rabbit IgG as control, and co-precipitating endogenous proteins were detected by 
western blot. The lower panel shows the inputs of co-IP experiment.  
B. HEK293T cells were transfected with independent siRNA for indicated genes 
(ARID1a in lanes 5 and 6; BAF53a in lanes 7 and 8; SNF5 in lanes 9 and 10) and 
siRNA control (in lanes 1, 2, 3 and 4) and with plasmid encoding Flag-BRG1 as 
indicated. Cell lysates were subjected to anti-Flag immunoprecipitation and 
co-precipitating endogenous proteins were checked by western blot. The inputs 
were checked by western blot (the lower panel).    
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Figure 10. YAP binds to ARID1a through its WW domain. 
A. Schematic representation depicting the multiple domains of YAP, and mapping 
the interactions with other proteins (Piccolo et al., 2014). The domains of YAP 
are presenting from C-terminal to N-terminal: PDZ Binding motif, TAD 
(Transcription Activation Domain), Coiled-Coil Domain, WW domain, TEAD 
Interacting Domain. 
B. Schematic representation of YAP deletion and mutation constructs used for the 
experiment depicted in Figures 10 C, D. 
C. HEK293T cells were transfected with the indicated YAP deletion constructs 
(Flag-tagged) described in Figure 10B. Protein extracts were subjected to 
anti-Flag IP and analyzed for coprecipitating endogenous ARID1A, BRG1, SNF5, 
AMOT, PTPN14 and TEAD4.  
D. HEK293T cells were transfected with the indicated YAP deletion or mutation 
constructs (Flag-tagged) described in Figure 10B. Protein extracts were subjected 
to anti-Flag IP and analyzed for coprecipitating endogenous ARID1a, SNF5, 
AMOT, PTPN14 and TEAD4. 
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Figure 11. F-actin binding to SWI/SNF causes YAP to dissociate from 
SWI/SNF 
A. Schematic representation of experiment depicted in Figure 11B.  
B. HEK293T cells were either left untreated or treated with Lat.A. Bio-Phall was 
added to the lysates after harvesting. Lysates were then subjected to Bio-Phall 
pulldown using streptavidin resin. Precipitating proteins were visualized by 
western blot. Inputs are shown in lane 1. 
C. MII cells were treated with either Lat.A or Phalloidin (Phall) for 4 hours. Lat.A 
or Phall were kept present in the lysates throughout all the following passages. 
Lysates were subjected to IP by using an anti-YAP antibody or rabbit IgG as 
control. Co-precipitating endogenous proteins were detected by western blot. 
Inputs were checked by western blot (lanes 5 and 6). 
D. MII cells were transfected with independent control siRNAs (lanes 1, 2 and 3, 
4) or siRNAs against ARID1A (lanes 5 and 6) and treated with Lat.A or Phall as 
indicated. Lysates were then subjected to IP by using an anti-YAP antibody or 
rabbit IgG as control. Co-precipitating endogenous proteins were detected by 
western blot. Inputs were checked by western blot (lower panel). 
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Figure 12. Knockdown of ARID1a rescues YAP activity in 
mechanically-inhibited cells 
A. Schematic representation of the experiment of Figures 12 B, C. 
B. and C. Loss of ARID1a rescues YAP/TAZ transcriptional activity in dense 
monolayers. MCF10a cells were transfected with independent siRNAs against 
ARID1a and with control siRNA. Then cells were seeded to obtain sparse cells or 
a dense monolayer. LMB were added to the cells two hours before harvesting for 
RNA. CTGF and CYR61 mRNA levels were checked by qRT-PCR and are 
normalized to GAPDH expression. 
D. and E. Loss of ARID1a rescues YAP/TAZ transcriptional activity in soft ECM. 
MCF10A cells were transfected with independent siRNAs against ARID1a and 
with control siRNA. Next, cells were seeded on a stiff substrate or a soft substrate. 
Then cells were harvest for RNA extraction. CTGF and PTX3 mRNA levels were 
checked by qRT-PCR and are normalized to GAPDH expression.  
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Figure 13. SWI/SNF complexes work as YAP inhibitors in Neurons 
A. Schematic representation of the experiment of Figure 13B. Neurons plated on 
plastic were infected with lentiviruses encoding for tetO-YAP and rtTA.  Mature 
neurons were selected by culturing them in neuronal medium containing the 
anti-mitotic drug AraC. After selection, neurons were infected with lentiviruses 
encoding the indicated shRNA (shCo, shBrm or shArid1a). After 24 hours of 
infection, medium was changed to NSC medium supplemented with doxycycline 
(see Methods). Generally, 15 days after inducing exogenous YAP in neurons, 
reprogrammed “NSC-like” spheres could be counted. 
B. Representative images of neurospheres formed in the different conditions. 
C. Quantification of the number of neurospheres formed by each of the samples 
depicted in Figure 13B. 
D. shArid1a and shBrm knockdown efficiencies in neurons were checked by 
qRT-PCR. 
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Figure 14. YAP-induced reprogramming is under mechanical regulation 
A. Schematic overview of YAP-induced reprogramming in neurons plated either 
on stiff substrate or on soft substrate.  
B, C. Representative images (B) and quantifications (C) of “NSC-like” 
neurospheres formed by YAP-expressing neuron plated on stiff substrate or on 
soft substrate.  
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Figure 15. Loss of SWI/SNF complex could help YAP to overcome 
mechanoregulation. 
A. Schematic overview of YAP-induced reprogramming of neurons plated on a 
soft substrate.  
B. Representative images and quantifications of neurospheres formed by 
Arid1a-depleted neurons after YAP-induced reprogramming. 
C. Representative images and quantifications of neurospheres formed by 
Brm-depleted neurons after YAP-induced reprogramming. 
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Figure 16. Loss of SWI/SNF complex facilitate YAP induced reprogramming 
and overcome mechanoregulation.  
 Immunofluorescence for the neuron marker NeuN and neuron stem cell marker 
SOX2 during YAP-induced reprogramming in the indicated conditions.   
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